Retigabine

DRUG5 trials

Sponsors

GlaxoSmithKline, Bausch Health Americas, Inc., University Hospital of Mont-Godinne

Conditions

EpilepsyEpilepsy, PartialPostherpetic NeuralgiaSeizures

Phase 1

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

WithdrawnNCT01691872

GlaxoSmithKlineEpilepsy, Partial

Start: 2012-10-10End: 2012-10-18Updated: 2018-09-17

Phase 2

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

CompletedNCT00612105

Bausch Health Americas, Inc.Postherpetic Neuralgia

Start: 2007-10-31End: 2009-12-31Updated: 2018-05-08

Phase 3

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

CompletedNCT00232596

GlaxoSmithKlineSeizures

Start: 2005-09-30End: 2008-01-31Updated: 2016-12-08

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

CompletedNCT00235755

GlaxoSmithKlineSeizures

Start: 2005-12-31End: 2008-04-30Updated: 2017-04-21

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study

CompletedNCT01823159

University Hospital of Mont-GodinneEpilepsy

Start: 2013-04-30End: 2014-01-31Updated: 2014-12-02

Related Papers

Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.

2012-04-1631 citations